Local delivery of Shisa3 mRNA or AAV‐Shisa3 transducted macrophages showed a superior effect when combined with PD‐1 blockade, suggesting that SHISA3 is a novel target for cancer immunotherapy. Here, SHISA3 is linked to cancer.